UCB S.A.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jean-Christophe Tellier
- Full Time Employees
- 10,117
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Allée de la Recherche, 60 Brussels BU Belgium 1070
- IPO Date
- Jan 2, 1987
- Website
- ucb.com
- Similar Companies
- Business
- UCB SA is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines and solutions for people living with severe neurological and immunology diseases. The company operates through three main business segments: neurology, immunology, and established brands; it offers a portfolio of branded prescription products including Briviact (brivaracetam) and Vimpat (lacosamide) for epilepsy; Bimzelx (bimekizumab) for plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; Cimzia (certolizumab pegol) for ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, and polyarticular juvenile idiopathic arthritis; Evenity (romosozumab) for osteoporosis; Fintepla (fenfluramine) for Dravet syndrome and Lennox-Gastaut syndrome; Keppra (levetiracetam) for epilepsy; Nayzilam (midazolam nasal spray) for epilepsy; Neupro (rotigotine) for Parkinson's disease and restless legs syndrome; RYSTIGGO (rozanolixizumab-noli) for myasthenia gravis; and ZILBRYSQ (zilucoplan) for myasthenia gravis. UCB conducts operations in approximately 40 countries worldwide, including key markets in the U.S., Europe (such as Germany, France, Italy, U.K., Ireland, and Belgium), Japan, China, and others, with around 9,000 employees supporting its activities. Founded in 1928 and headquartered in Brussels, Belgium, at Allée de la Recherche 60, the company generated revenue of €6.1 billion in 2024. Recent strategic changes include the completion in November 2024 of the sale of rights to established brands Atarax and Nootropil for Europe and select countries in Latin America and Asia-Pacific to ADVANZ PHARMA, generating €64 million in net sales in 2023 for these products and enabling UCB to update its 2024 financial guidance to revenue near €6 billion and an adjusted EBITDA margin in the upper part of 23.0-24.5%; a carve-out in August 2024 of its mature business in China, with 100% ownership acquired by Mubadala Investment Company in partnership with CBC Group to reinforce long-term commitment in Asia; and a strategic executive leadership rotation announced in November 2025, effective January 1, 2026, appointing Fiona du Monceau as Chief Commercial Officer and Emmanuel Caeymaex as Head of Patient Evidence to drive future growth and innovation.
Company News
UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
United Community Banks, Inc. (UCB) Q3 2026 Earnings Call Transcript
What United Community Banks (UCB) Said on Its Q3 Earnings Call
United Community Banks (UCB) Reports Q3 Earnings: What Key Metrics Have to Say
United Community Banks (UCB) Q3 Earnings Match Estimates
United Community Banks (UCB) Reports Next Week: Wall Street Expects Earnings Growth
UCB SA (UCBJY) Discusses EADV Data Highlights and Long-Term Impact of BIMZELX in Dermatology Transcript
UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Moderate Buy” from Brokerages
UCB (OTCMKTS:UCBJY) Reaches New 1-Year Low – Should You Sell?
Why United Community Banks (UCB) is a Great Dividend Stock Right Now
UCB SA (UCBJY) Presents at J.P. Morgan CEO Call Series Transcript
UCB SA (UCBJY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
UCB (UCBJY) Upgraded to Buy: Here's Why
Why United Community Banks (UCB) is a Top Dividend Stock for Your Portfolio
United Community Banks, Inc. (UCB) Discusses Completion of Strategic Initiatives and Sale of Navitas to Strengthen Financial Position Transcript
Trump's MFN Push Goes Beyond Big Pharma, Adds 9 Mid-Sized Drugmakers
United Community Banks (UCB) is a Top Dividend Stock Right Now: Should You Buy?
UCB (OTCMKTS:UCBJY) Stock Crosses Below Two Hundred Day Moving Average – Should You Sell?
United Community Banks (UCB) Could Be a Great Choice
UCB SA (UCBJY) Q2 2026 Earnings Call Transcript